Updated
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data

Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.

Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.

Pfizer
Pharma’s Ghost Labs Find New Life
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Mar 31, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The Rising Research Profile of 23andMe
The Rising Research Profile of 23andMe
Catherine Offord | Nov 30, 2017
An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.
Pfizer to Buy Medivation for $14 Billion
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
NYU Halts Studies, Suspends Investigator
NYU Halts Studies, Suspends Investigator
Bob Grant | Jun 28, 2016
Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.
Pfizer Scoops Anacor for $5.3 Billion
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 17, 2016
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Pfizer-Allergan Merger Scrapped
Pfizer-Allergan Merger Scrapped
Bob Grant | Apr 7, 2016
A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.
Pfizer and Allergan to Merge
Pfizer and Allergan to Merge
Bob Grant | Nov 23, 2015
The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.
Pfizer to Acquire Hospira
Pfizer to Acquire Hospira
Bob Grant | Feb 5, 2015
The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.